37 results about "Merokeratin" patented technology

The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry. The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16[INK4A] antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.

The invention relates to a quantum dot fluorescent probe and application thereof. The invention is characterized in that the quantum dot fluorescent probe utilizes a difunctional cross-linking agent long-chain succinimidyl-4-[N-maieimidomethyl]cyclohexane-1-carboxy-[6-amidocaproate] (SMCC) to undergo a cross-linking reaction with an amino group on the surface of an amino quantum dot; a maleimide group is produced on the surface of the quantum dot; a to-be-labeled antibody is reduced by a reducing agent dithiothreitol (DTT) so as to reduce a disulfide bond into a mercapto group; and the mercapto group and the maleimide group form a covalent bond so as to realize labeling of the quantum dot with the antibody. The quantum dot fluorescent probe is applied to (1) detection of one protein oncofetal antigen or (2) detection of a plurality of protein CEA, euron-specific enolase (NSA) and a cytokerain fragment 19CYFRA21-1, wherein the detection limit of detection (1) is 38 pg / ml, and the detection limit of detection (2) is 0.9 ng / ml.

The present invention relates to enrichment and / or identification of fetal cells of a maternal blood sample using fetal cell specific ligands and / or fetal cell specific hybridization probes wherein the ligand or probes are directed to an endothelial / mesenchymal marker, e.g. CD105, CD146 or CD141, in a first round of enrichment and the ligand or probes, in a second round of enrichment, are directed to an epithelial marker, e.g. a cytokeratin, such as CK7, CK8, CK18 or CK19. Enriched or identified fetal cells may be subjected to steps of detection or diagnosis, wherefore the present invention enables non- invasive 5 prenatal diagnostics.

The invention relates to a plate-type chemiluminescence detection kit of a cytokeratin 19-fragment. The kit comprises the following reagents: biotin-marked CYFRA21-1 antibody solution, an elisa plate coated by anti-biotin, horse-radish-peroxidase-marked CYFRA21-1 antibody solution, a CYFRA21-1 calibration product A-F, concentrated washing liquor, substrate solution A, and substrate solution B. The main design idea of the detection kit is that the detection specificity of the kit is stabilized by introducing a biotin system with the anti-biotin on the basis of chemiluminescence immune assay, and the detection sensitivity and detection time are greatly increased. A high-temperature oscillatory-type anti-biotin coating technology is improved, so the usage amount of antibodies / antigens is reduced, the production flow of the reagents is simplified, and the production cycle is shortened.

The invention relates to a cytokeratin 18 gene expression detection kit and a detection method thereof. The cytokeratin 18 gene expression detection kit comprises a capture probe aiming at CK18 gene mRNA and a signal amplification system, the capture probe is a stem-ring-shaped gamma PNA-PNA probe, which sequentially comprises a stem structure sequence, a P1 sequence, a Linker sequence and a P2 sequence from the 5' end to the 3' end; and the signal amplification system comprises a marking probe SP1 and a marking probe SP2, wherein each labeled probe SP1 sequentially comprises a P3 sequence, a spacer sequence and a P4 sequence from the 5' end to the 3' end; the 5' end of the P3 sequence is modified with a fluorophore, each labeled probe SP2 sequentially comprises a P5 sequence, a spacer sequence and a P6 sequence from the 5' end to the 3' end, and the 3' end of the P6 sequence is modified with a fluorophore. The kit has the advantages of high sensitivity, strong specificity, high accuracy, short detection time and the like.

The invention discloses a lung cancer risk prediction model for Chinese rural population with pulmonary nodules based on biomarker spectrum, which consists of biomarkers and their enzyme-labeled antibodies, a carbonate buffer solution with a pH value of 9.6, and a pH value of 7.4 Phosphate buffer solution, serum protein dilution, stop solution, tetramethylbenzidine substrate solution, normal human serum and positive control serum; the biomarkers include gastrin releasing propeptide, carcinoembryonic antigen 4 biomarkers, including fragments of cytokeratin 19 and squamous cell carcinoma antigen, and combined with other clinical indicators. The present invention can assist in screening for lung cancer.

The invention discloses a lung cancer risk prediction model based on CT images and biomarker spectrum for Chinese urban population with pulmonary nodules. Phosphate buffer solution with a value of 7.4, serum protein dilution, stop solution, tetramethylbenzidine substrate solution, normal human serum and positive control serum; the biomarkers include gastrin-releasing propeptide, Four biomarkers including carcinoembryonic antigen, fragment of cytokeratin 19 and squamous cell carcinoma antigen were combined with CT imaging parameters and other clinical indicators. The present invention can assist in screening for lung cancer.

The invention relates to a preparation method of an electrochemical immunosensor based on a polypyrrole modified silver phosphate loaded silver nanosphere composite material. According to the invention, a primary antibody marker is formed by internal packaging of a Prussian blue analogue (NiFe@FeFe PBA) with a core-shell heterostructure and combination of a primary antibody externally loaded with luminol and a soluble fragment of cytokeratin 19; and a polypyrrole modified silver phosphate loaded silver nanosphere composite material (Ag3PO4@PPy-Ag) is combined with a second antibody of a soluble fragment of cytokeratin 19 to form a second antibody marker, so that the construction process of the sensor is simplified. Luminol is packaged into a porous core-shell heterostructure nanocube NiFe@FeFe PBA, so that the nano composite material with an excellent electrochemical luminescence behavior is obtained. Ag3PO4@PPy-Ag can effectively quench electrochemical luminescence of luminol, a sandwich quenching type electrochemical immunosensor is constructed based on the resonance energy transfer principle, ultra-sensitive detection of soluble fragments of cytokeratin 19 is achieved, and the detection limit is 28.43 fg mL <-1>.

The invention provides a radionuclide targeted breast cancer sentinel lymph node metastasis tracer and a preparation method thereof. The tracer comprises a cytokeratin 19 (CK19) monoclonal antibody and pertechnetate, and the pertechnetate is subjected to a reaction through 2-mercaptoethanol and is coupled to the CK19 monoclonal antibody. The preparation method comprises the following steps of performing a mixed reaction on the CK19 monoclonal antibody with the 2-mercaptoethanol, adding micromolecular dextran to be uniformly mixed, adding sodium glucoheptonate, stannous chloride and sodium pertechnetate for a reaction, and performing separation by adopting a PD-10 column. The tracer prepared by the method can effectively reduce local trauma of a patient by detecting the metastasis conditionof sentinel lymph nodes in vivo, provides a favorable decision basis for surgeons, and shortens the operation time of the patient.

An immortalized sweat gland myoepithelial cell which expresses α-SMA and pan-cytokeratin and has a sphere forming ability after subculture at least 5 times. A method for producing immortalized sweat gland myoepithelial said method comprising: while culturing a cell structure, wherein sweat gland myoepithelial cells are exposed on a surface, in a state of being suspended in a medium, transferring an immortalizing gene into the cells; and then culturing the transgenic structure thus obtained in a state of being suspended in the medium to thereby obtain immortalized sweat gland myoepithelial cells.

The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.

The invention provides a method for preparing a porous material on the basis of wool keratin cortex cells, and belongs to the field of preparation of a high molecular material. The method comprises the steps of: firstly, preparing cortex cell aqueous suspension by taking the wool keratin cortex cells as a raw material; then adding glutaraldehyde into the cortex cell aqueous suspension, and carrying out magnetic stirring to obtain uniform milk white suspension; then rapidly placing the milk white suspension at a temperature of minus 40 DEG C to freeze, and then carrying out vacuum freezing drying; and finally, placing a sample after vacuum freezing drying into a baking oven to bake, and enabling the glutaraldehyde and keratin to be cross-linked so as to obtain the wool cortex cell porous material. According to the invention, the porous material with a large gap is prepared with the simple method, can be used in the fields of heat preservation, heat insulation, damping and the like, andbelongs to the technical field of the high molecular material.

The invention provides a wool keratin cortex cell preparation method, and belongs to the field of wool keratin cortex cell extraction. The method includes the steps: firstly, pretreating wool by calcium hypochlorite / hydrogen peroxide and stripping wool surface scale layers; secondly, taking L-cysteine as a reducing agent, performing trypsin catalysis and degrading wool fibers by CMC (carboxymethylcellulose) to separate wool cortex cells; thirdly, further separating the cortex cells by ultrasonic treatment; finally, filtering and sucking filtrate to obtain the cortex cells and freezing and drying the cortex cells to obtain wool keratin cortex cells. The method is efficient and environmentally friendly.